Cover Image
市場調查報告書

急性前骨髓球性白血病(APL)的開發中產品分析

Acute Promyelocytic Leukemia - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 245995
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
急性前骨髓球性白血病(APL)的開發中產品分析 Acute Promyelocytic Leukemia - Pipeline Review, H1 2014
出版日期: 2014年05月15日 內容資訊: 英文 44 Pages
簡介

急性前骨髓球性白血病(APL)是急性白血病的一種,有著獨特的細胞遺傳學上特質和臨床性特徵、生物學性性質。急性前骨髓球性白血病是因腫瘤化(白血病發病)的造血細胞停滯於分化前骨髓球階段而發病。

本報告提供全球各國治療急性前骨髓球性白血病(APL)用的開發中產品開發情形相關分析,彙整開發中產品最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

急性前骨髓球性白血病概要

治療藥的開發

  • 急性前骨髓球性白血病開發中產品:概要
  • 急性前骨髓球性白血病開發中產品:比較分析

各企業正開發中的急性前骨髓球性白血病治療藥

大學/研究機關研究中的急性前骨髓球性白血病治療藥

開發中產品概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

急性前骨髓球性白血病治療藥:開發中產品一覽(各企業)

急性前骨髓球性白血病治療藥:研究中產品一覽(大學/研究機關別)

急性前骨髓球性白血病治療藥的開發企業

  • 東光藥品工業

急性前骨髓球性白血病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 分子的各類型
  • 各治療分類

藥物簡介

  • tamibarotene
  • tamibarotene
  • Myc-Max Compounds
  • 5-Hydroxy-2, 3-Indole Derivatives
  • DR4 Specific Mutant TRAIL Proteins
  • Combretastatin類似體

急性前骨髓球性白血病治療藥:最新的藥物簡介

急性前骨髓球性白血病治療藥:暫停開發的產品

急性前骨髓球性白血病相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全4件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5043IDB

Global Markets Direct's, 'Acute Promyelocytic Leukemia - Pipeline Review, H1 2014', provides an overview of the Acute Promyelocytic Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Promyelocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Promyelocytic Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Promyelocytic Leukemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Promyelocytic Leukemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Promyelocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Promyelocytic Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Promyelocytic Leukemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Promyelocytic Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Promyelocytic Leukemia Overview
  • Therapeutics Development
    • Pipeline Products for Acute Promyelocytic Leukemia - Overview
    • Pipeline Products for Acute Promyelocytic Leukemia - Comparative Analysis
  • Acute Promyelocytic Leukemia - Therapeutics under Development by Companies
  • Acute Promyelocytic Leukemia - Therapeutics under Investigation by Universities/Institutes
  • Acute Promyelocytic Leukemia - Pipeline Products Glance
  • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acute Promyelocytic Leukemia - Products under Development by Companies
  • Acute Promyelocytic Leukemia - Products under Investigation by Universities/Institutes
  • Acute Promyelocytic Leukemia - Companies Involved in Therapeutics Development
    • Teva Pharmaceutical Industries Limited
    • Toko Pharmaceutical Industries Co., Ltd.
  • Acute Promyelocytic Leukemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • tamibarotene - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omacetaxine mepesuccinate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Myc-Max Compounds - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • 5-Hydroxy-2, 3-Indole Derivatives - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DR4 Specific Mutant TRAIL Proteins - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Combretastatin Analogues - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acute Promyelocytic Leukemia - Recent Pipeline Updates
  • Acute Promyelocytic Leukemia - Dormant Projects
  • Acute Promyelocytic Leukemia - Product Development Milestones
    • Featured News & Press Releases
      • Aug 16, 2013: Epizyme Receives Orphan Drug Designation for EPZ-5676
      • Jul 09, 2012: CytRx Receives Notice Of Allowance Of US Patent Application For Tamibarotene Capsule
      • Apr 18, 2011: CytRx Announces Publication Of Peer-Reviewed Case Report Documenting Tamibarotene's Successful Elimination Of Recurrent Advanced-Stage Leukemia
      • Dec 07, 2009: CytRx Announces Positive Phase II Results Of Tamibarotene For The Treatment Of Relapsed Acute Promyelocytic Leukemia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Promyelocytic Leukemia, H1 2014
  • Number of Products under Development for Acute Promyelocytic Leukemia - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Acute Promyelocytic Leukemia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014
  • Acute Promyelocytic Leukemia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Acute Promyelocytic Leukemia Therapeutics - Recent Pipeline Updates, H1 2014
  • Acute Promyelocytic Leukemia - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Acute Promyelocytic Leukemia, H1 2014
  • Number of Products under Development for Acute Promyelocytic Leukemia - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top